Trials / Completed
CompletedNCT01638390
Use of the VisuMax™ Femtosecond Laser
Use of the VisuMax™ Femtosecond Laser Lenticule Removal Procedure for the Correction of Myopia
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 357 (actual)
- Sponsor
- Carl Zeiss Meditec, Inc. · Industry
- Sex
- All
- Age
- 22 Years
- Healthy volunteers
- Accepted
Summary
The objective of this clinical trial is to evaluate the safety and effectiveness of the Carl Zeiss Meditec VisuMax™ Femtosecond Laser lenticule removal procedure for the reduction or elimination of myopia from ≥ -1.00 D to ≤ -8.00 D with ≤ -0.50 D cylinder and MRSE (Manifest Refractive Spherical Equivalent) ≤ -8.25 D.
Detailed description
This is a prospective multi-center clinical trial in which a total of 360 eyes of consecutive subjects will be enrolled, treated with the VisuMax™ Femtosecond Laser, and followed for a 12-month period. The study will be conducted at up to 8 clinical sites. Enrollment will be phased such that 100 eyes will be initially enrolled and followed. When 50 of the initial eyes have reached the 3-month follow-up exam, an interim clinical study report will be submitted to FDA along with a request to continue enrollment up to 360 eyes. Subjects will be screened for eligibility, and informed consent will be obtained from those who meet screening criteria and are interested in participating in the study. Eligible subjects will be examined preoperatively to obtain a medical history and to establish a baseline ocular condition. Baseline and postoperative measurements will include manifest refraction, cycloplegic refraction, distance visual acuity (best corrected and uncorrected), slit-lamp examination, fundus examination, corneal topography, central corneal pachymetry, mesopic pupil measurement, wavefront analysis, mesopic contrast sensitivity, and intraocular pressure (IOP).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Treatment with the VisuMax™ Femtosecond Laser | The reduction or elimination of myopia from ≥ -1.00 D to ≤ -8.00 D with ≤ -0.50 D cylinder and MRSE ≤ -8.25 D. |
Timeline
- Start date
- 2012-07-01
- Primary completion
- 2016-04-01
- Completion
- 2016-04-01
- First posted
- 2012-07-11
- Last updated
- 2026-04-02
- Results posted
- 2019-03-21
Locations
5 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01638390. Inclusion in this directory is not an endorsement.